Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Yevhen Hotko"'
Autor:
Scott D. Patterson, Roger Sidhu, Andre S. Jung, Jan-Henrik Terwey, Reija Koukakis, Hua Yu, Pei He, Eric Van Cutsem, Laslo Roman, Tudor E. Ciuleanu, Gregory Wilson, Andrew H. Strickland, Cornelis J.A. Punt, Florian Lordick, Emily Chan, Thierry André, Yevhen Hotko, Michel Ducreux, Alberto F. Sobrero, Andrés Cervantes, Timothy J. Price, Kelly S. Oliner, Marc Peeters
Contains: Table S1. RAS and BRAF Mutation Status Table S2. Objective Response Rate in Patients with Mutated RAS Table S3. Depth of Response and Early Tumor Response in Wild-type KRAS Exon 2 Patients Figure S1. Disposition of patients in the study and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a270e11af1fd12d264083118e64d68d8
https://doi.org/10.1158/1078-0432.22460478
https://doi.org/10.1158/1078-0432.22460478
Autor:
Scott D. Patterson, Roger Sidhu, Andre S. Jung, Jan-Henrik Terwey, Reija Koukakis, Hua Yu, Pei He, Eric Van Cutsem, Laslo Roman, Tudor E. Ciuleanu, Gregory Wilson, Andrew H. Strickland, Cornelis J.A. Punt, Florian Lordick, Emily Chan, Thierry André, Yevhen Hotko, Michel Ducreux, Alberto F. Sobrero, Andrés Cervantes, Timothy J. Price, Kelly S. Oliner, Marc Peeters
Purpose: We evaluated the influence of RAS mutation status on the treatment effect of panitumumab in a prospective–retrospective analysis of a randomized, multicenter phase III study of panitumumab plus fluorouracil, leucovorin, and irinotecan (FOL
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::236fc56665240edab4fb993d5fdfdc8c
https://doi.org/10.1158/1078-0432.c.6524502
https://doi.org/10.1158/1078-0432.c.6524502
Autor:
Mafalda Oliveira, Denys Pominchuck, Zbigniew Nowecki, Erika Hamilton, Yaroslav Kulyaba, Timur Andabekov, Yevhen Hotko, Tamar Melkadze, Gia Nemsadze, Patrick Neven, Yuriy Semegen, Vladmir Vladmirov, Claudio Zamagni, Hannelore Denys, Frederic Forget, Zsolt Horvath, Alfiya Nesterova, Maxine Bennett, Bistra Kirova, Teresa Klinowska, Justin Lindemann, Delphine Lissa, Alastair Mathewson, Christopher Morrow, Zuzana Traugottova, Ruaan Van Zyl, Ekaterine Arkania
Publikováno v:
Cancer Research. 83:GS3-02
Background Camizestrant (C), a next-generation oral selective estrogen receptor (ER) antagonist and degrader (ngSERD) has shown promising clinical activity in ER+ breast cancer (BC) in the Phase 1 SERENA-1 study1,2 with a dose-dependent safety profil
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::12e1c7074b8ccc605160741e8e23510e
https://doi.org/10.1158/1538-7445.sabcs22-gs3-02
https://doi.org/10.1158/1538-7445.sabcs22-gs3-02
Autor:
Yevhen Hotko
Background Male mammary glands are usually considered a rudimentary organ. However, they may be exposed to similar pathological influences as female breasts. These pathological influences may cause the development of malignant breast tumors. Breast c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::78d18d39e9968e01cc28d68fe5064b07
https://doi.org/10.21203/rs.3.rs-78098/v1
https://doi.org/10.21203/rs.3.rs-78098/v1
Autor:
Yaroslav Shparyk, Andrew D. Seidman, Yee Soo Chae, Lee S. Schwartzberg, Thomas Wei, Yevhen Hotko, Yen-Shen Lu, Sina Vatandoust, Sara M. Tolaney, Noshir Anthony Dacosta, Sabela Recalde, Chi-Feng Chung, Igor Bondarenko, Hope S. Rugo, Nuria Chic, Patricia Gomez, Joyce O'Shaughnessy, Joe O'Connell, Lawrence Panasci, Gail Lynn Shaw Wright
Publikováno v:
Journal of Clinical Oncology. 39:1061-1061
1061 Research Funding: Odonate Therapeutics, Inc. Background: T is a novel, oral taxane with unique properties, including: oral administration with a low pill burden, a long (8-day) half-life in humans, once-every-3-weeks dosing, no observed hypersen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d280d911490967d57c181424257b351a
https://doi.org/10.1200/jco.2021.39.15_suppl.1061
https://doi.org/10.1200/jco.2021.39.15_suppl.1061
Autor:
Ulrich Gatzemeier, Igor Bondarenko, Yevhen Hotko, Jae Kyung Roh, Christopher Stroh, Cornelius Kortsik, Kenneth J. O'Byrne, Rodryg Ramlau, Carlos H. Barrios, Corinna Eschbach, Robert Pirker, Chih Teng Yu, Armin Schueler, Uwe M. Martens, Luis Paz-Ares, Joachim von Pawel, José Rodrigues Pereira, Ilhan Celik
Publikováno v:
The Lancet Oncology. 12:795-805
Findings from the phase 3 FLEX study showed that the addition of cetuximab to cisplatin and vinorelbine significantly improved overall survival, compared with cisplatin and vinorelbine alone, in the first-line treatment of EGFR-expressing, advanced n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1c2b7404580140d5c63357f430072e3
https://doi.org/10.1016/s1470-2045(11)70189-9
https://doi.org/10.1016/s1470-2045(11)70189-9
Autor:
Fred B. Oldham, Yevhen Hotko, Jack W. Singer, Valentin L. Ganul, Mary O'Brien, Mark A. Socinski, Igor Bondarenko, B. Bandstra, Alan B. Sandler, Antoaneta Tomova, Larissa Sandalic, Borys T. Bilynsky˘ı, Amy J. Eisenfeld, Ippolit Y. Kostinsky, Alexander Y. Popovich
Publikováno v:
Journal of Thoracic Oncology. 3:728-734
Background Patients with advanced non-small cell lung cancer (NSCLC) and impaired performance status (PS ≥ 2) have limited life expectancies and decreased tolerance for drug-induced toxicities. Current treatment guidelines indicate that PS 2 patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::818cd7daaf1ef13620b7c30a8f8245e3
https://doi.org/10.1097/jto.0b013e31817c6b68
https://doi.org/10.1097/jto.0b013e31817c6b68
Autor:
Pei He, Andrew Strickland, Florian Lordick, Eric Van Cutsem, Gregory C. Wilson, Andrés Cervantes, Laslo Roman, Emily Chan, Cornelis J. A. Punt, Kelly S. Oliner, Reija Koukakis, Timothy J. Price, Hua Yu, Jan Henrik Terwey, Michel Ducreux, A.S. Jung, Marc Peeters, Yevhen Hotko, Thierry André, Roger Sidhu, Tudor Ciuleanu, Alberto Sobrero, Scott D. Patterson
Publikováno v:
Clinical cancer research
Clinical cancer research, 21(24), 5469-5479. American Association for Cancer Research Inc.
Clinical cancer research, 21(24), 5469-5479. American Association for Cancer Research Inc.
Purpose: We evaluated the influence of RAS mutation status on the treatment effect of panitumumab in a prospective–retrospective analysis of a randomized, multicenter phase III study of panitumumab plus fluorouracil, leucovorin, and irinotecan (FOL
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25b49609c0922c00f2501f83b8f2b6ef
https://hdl.handle.net/10067/1311020151162165141
https://hdl.handle.net/10067/1311020151162165141
Autor:
Sadie Whittaker, Zandra Klippel, Peter Gibbs, Adina Croitoru, Mi Rim Choi, Tamás Pintér, Jacek Jassem, Yevhen Hotko, Tomas Salek, Seamus O'Reilly, Jan Novotny, Jochen Decaestecker, G. Kurteva, Phuong Khanh Morrow, Charles D. Blanke, Alvydas Česas, Maureen Reiner
Publikováno v:
Clinical Colorectal Cancer. 16:103-114.e3
Background Pegfilgrastim's role in reducing the risk of febrile neutropenia (FN) in patients with colorectal cancer (CRC) receiving chemotherapy plus bevacizumab was not previously evaluated in a prospective study. The present phase III, double-blind
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e4a9d8c040b21c5939d87970343502c
https://doi.org/10.1016/j.clcc.2016.08.008
https://doi.org/10.1016/j.clcc.2016.08.008
Autor:
Yevhen Hotko, Andrew Strickland, Roger Sidhu, Lynda D. Roman, Ying Tian, Thierry André, G. Wilson, Andrés Cervantes, Tudor-Eliade Ciuleanu, Michel Ducreux, Alberto Sobrero, Florian Lordick, Emily Chan, Marc Peeters, E. Van Cutsem, C.J.A. Punt, Timothy J. Price
Publikováno v:
Annals of oncology
Annals of oncology, 25(1), 107-116. Oxford University Press
Annals of oncology, 25(1), 107-116. Oxford University Press
Background: The study 20050181 demonstrated significant improvements in progression-free survival (PFS), objective response, and a nonsignificant trend toward increased overall survival (OS) with panitumumab-FOLFIRI versus FOLFIRI alone for second-li
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce54a0a6ec2cc52ee1e8c6436df916ce
https://hdl.handle.net/10067/1158330151162165141
https://hdl.handle.net/10067/1158330151162165141